One of the few bright spots in Boston’s life-science lab space market this year has dimmed.

Ginkgo Bioworks reported mixed Q3, with a $45M one-time revenue boost masking underlying revenue growth issues. Read why I ...

Ginkgo Bioworks is offering its newly-completed Boston Seaport lab complex for sublease as it shrinks its real estate ...

BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $6 from $7 and keeps a Sell rating on the shares ...

Ginkgo Bioworks is headquartered at 27 Drydock Avenue in Boston's Seaport. Ginkgo has canceled its planned move into a ...

Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...

Ginkgo Bioworks Holdings, Inc. ( (DNA)) has released its Q3 earnings. Here is a breakdown of the information Ginkgo Bioworks Holdings, Inc. presented to its investors. Ginkgo Bioworks Holdings, Inc.

Boston: Ginkgo Bioworks has announced the completion of the first milestone of a previously announced partnership with Merck, ...

Q3 2024 Earnings Call Transcript November 12, 2024 Megan LeDuc: Good evening. I’m Megan LeDuc, Manager of Investor Relations ...

Ginkgo Bioworks advances collaboration with Merck to improve biologics manufacturing; Ginkgo to receive a research milestone payment of $9 million: Boston, Massachusetts Thursday, ...

Revenue: US$89.0m (up 61% from 3Q 2023). Net loss: US$56.4m (loss narrowed by 81% from 3Q 2023). US$1.08 loss per share (improved from US$6.21 loss in 3Q 2023). Revenue exceeded analyst estimates ...

Ginkgo Bioworks Holdings Inc, based in Boston, Massachusetts, specializes in cell programming to revolutionize the production of various products. By manipulating cells, they create novel ...